Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal.
Sadoul, J L
Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal. [electronic resource] - Acta endocrinologica Feb 1992 - 179-83 p. digital
Publication Type: Case Reports; Journal Article
0001-5598
10.1530/acta.0.1260179 doi
Adenoma--drug therapy
Adult
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bromocriptine--administration & dosage
Growth Hormone--metabolism
Humans
Magnetic Resonance Imaging
Male
Octreotide--administration & dosage
Pituitary Neoplasms--drug therapy
Prolactin--metabolism
Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal. [electronic resource] - Acta endocrinologica Feb 1992 - 179-83 p. digital
Publication Type: Case Reports; Journal Article
0001-5598
10.1530/acta.0.1260179 doi
Adenoma--drug therapy
Adult
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bromocriptine--administration & dosage
Growth Hormone--metabolism
Humans
Magnetic Resonance Imaging
Male
Octreotide--administration & dosage
Pituitary Neoplasms--drug therapy
Prolactin--metabolism